Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Minority Patients With Moderate to Severe Asthma
NCT00180011Phase 3Completed
- Sponsor
- DiMango
- Start
- Sep 2005
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab in allergic asthma, sponsored by DiMango. Primary endpoint: Asthma Symptom Utility Index at 6 months. Started Sep 2005; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00180011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00180011.